Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Janakiraman Subramanian"'
Autor:
Himil Mahadevia, Ben Ponvilawan, Ammar Al-Obaidi, Jennifer Buckley, Janakiraman Subramanian, Dhruv Bansal
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in various tumors. A significant therapeutic challenge with either ICIs or PARP inhibitors as monotherapy is treatment failure from intrinsic p
Externí odkaz:
https://doaj.org/article/4fb5286f5f1d46a8a961bf50d89e628a
Autor:
Elizabeth Marrett, Winghan Jacqueline Kwong, Jipan Xie, Ameur M. Manceur, Selvam R. Sendhil, Eric Wu, Raluca Ionescu-Ittu, Janakiraman Subramanian
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 531-544 (2023)
Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR TKIs) are established first-line treatments among patients with metastatic non-small cell lung cancer harboring EGFR-sensitizing mutations. Upon EGFR TKI resistance
Externí odkaz:
https://doaj.org/article/9caad38b62b441cfafd81f36ac1d42c7
Autor:
Jacob Sands, Janakiraman Subramanian
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or durvalumab.
Externí odkaz:
https://doaj.org/article/bbf4b8a98e1c4e0bae8085daf46477e7
Autor:
Sravani Akula, Sai Charitha Mullaguri, Niklas Max Melton, Archana Katta, Venkata Sai Giridhar Reddy Naga, Shyamson Kandula, Raj Kumar Pedada, Janakiraman Subramanian, Rama Krishna Kancha
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17468-17474 (2023)
Abstract Background Mutations in kinases are the most frequent genetic alterations in cancer; however, experimental evidence establishing their cancerous nature is available only for a small fraction of these mutants. Aims Predicition analysis of kin
Externí odkaz:
https://doaj.org/article/e7fbbda0df94487197d9dc00e823a0e8
Publikováno v:
Cancers, Vol 16, Iss 6, p 1225 (2024)
Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatmen
Externí odkaz:
https://doaj.org/article/93034bddf24643e1adfb03fd8646a2c1
Autor:
Chris Ward, Nikita Kotlov, Krystle Nomie, Konstantin Danilov, Dhruv Bansal, Ivan Valiev, Vladimir Kushnarev, Ammar Al-Obaidi, Timothy Pluard, Artem Tarasov, Anastasiia Makarova, Anna Butusova, Anna Love, Janakiraman Subramanian, Alexander Bagaev
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/27d38196c775467cbd6d7fbde29871cd
Autor:
Ateeq M. Khaliq, Cihat Erdogan, Zeyneb Kurt, Sultan Sevgi Turgut, Miles W. Grunvald, Tim Rand, Sonal Khare, Jeffrey A. Borgia, Dana M. Hayden, Sam G. Pappas, Henry R. Govekar, Audrey E. Kam, Jochen Reiser, Kiran Turaga, Milan Radovich, Yong Zang, Yingjie Qiu, Yunlong Liu, Melissa L. Fishel, Anita Turk, Vineet Gupta, Ram Al-Sabti, Janakiraman Subramanian, Timothy M. Kuzel, Anguraj Sadanandam, Levi Waldron, Arif Hussain, Mohammad Saleem, Bassel El-Rayes, Ameen A. Salahudeen, Ashiq Masood
Publikováno v:
Genome Biology, Vol 23, Iss 1, Pp 1-30 (2022)
Abstract Background Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different immunological, stromal cell, and clinicopathological characteristics. Single-cell characterization of CMS subtype tumor microenvironments is required to elu
Externí odkaz:
https://doaj.org/article/ae2d60102a98447596fa9e335944c864
Autor:
Ashiq Masood, Trevor Christ, Samia Asif, Priya Rajakumar, Beth A. Gustafson, Leyla O. Shune, Ameen Salahudeen, Drew Nedvad, Suparna Nanua, Agne Paner, Timothy M. Kuzel, Mia Levy, Janakiraman Subramanian, Shahzad Raza
Publikováno v:
npj Genomic Medicine, Vol 6, Iss 1, Pp 1-5 (2021)
Abstract Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the ge
Externí odkaz:
https://doaj.org/article/31e8f416ebe34f07bee1c287af92fbac
Autor:
Anne C. Chiang, Ancilla W. Fernandes, Melissa Pavilack, Jennifer W. Wu, François Laliberté, Mei Sheng Duh, Nabil Chehab, Janakiraman Subramanian
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background The objective of this study was to investigate real-world EGFR mutation testing in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on first−/second-generation epidermal growth factor receptor (EGFR)-
Externí odkaz:
https://doaj.org/article/4acb467ab69141d794fec14693edc72b
Autor:
Ateeq M. Khaliq, Cihat Erdogan, Zeyneb Kurt, Sultan Sevgi Turgut, Miles W. Grunvald, Tim Rand, Sonal Khare, Jefrey A. Borgia, Dana M. Hayden, Sam G. Pappas, Henry R. Govekar, Audrey E. Kam, Jochen Reiser, Kiran Turaga, Milan Radovich, Yong Zang, Yingjie Qiu, Yunlong Liu, Melissa L. Fishel, Anita Turk, Vineet Gupta, Ram Al-Sabti, Janakiraman Subramanian, Timothy M. Kuzel, Anguraj Sadanandam, Levi Waldron, Arif Hussain, Mohammad Saleem, Bassel El-Rayes, Ameen A. Salahudeen, Ashiq Masood
Publikováno v:
Genome Biology, Vol 23, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/928eedb32bf34502b0a515c07684b7f6